Potential Role of Magrolimab in the Treatment of Higher-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)

home / precision-medicine / potential-role-of-magrolimab-in-the-treatment-of-higher-risk-myelodysplastic-syndrome-mds-and

Hetty Carraway, MD, and Eytan M. Stein, MD, discuss treatment options for patients with higher-risk myelodysplastic syndrome and acute myeloid leukemia, and how to select the best treatment regimen based on patient and disease factors.

EP. 1: An Overview of Myelodysplastic Syndrome (MDS)

Hetty E. Carraway, MD;Eytan M. Stein, MD

September 29th 2022

Eytan M. Stein, MD, provides an overview of myelodysplastic syndrome, including risk factors, symptoms, and diagnosis.

Watch

EP. 2: The Progression of Myelodysplastic Syndrome to Acute Myeloid Leukemia (AML)

Hetty E. Carraway, MD;Eytan M. Stein, MD

September 29th 2022

Hetty Carraway, MD, describes how MDS differs from acute myeloid leukemia (AML), and the percentage of patients who progress to AML from MDS.

Watch

EP. 3: Risk Stratification for Patients with Myelodysplastic Syndrome

Hetty E. Carraway, MD;Eytan M. Stein, MD

October 6th 2022

Dr Eytan M Stein breaks down how patients with MDS are risk-stratified, and how the clinical outcomes differ between risk groups.

Watch

EP. 4: Treatment Goals for Patients with Myelodysplastic Syndrome

Hetty E. Carraway, MD;Eytan M. Stein, MD

October 6th 2022

Experts explain the treatment goals for patients with MDS, and discusses the role of molecular testing in patients with MDS.

Watch

EP. 5: Currently Available Treatment Options for Patients with Higher-Risk Myelodysplastic Syndrome

Hetty E. Carraway, MD;Eytan M. Stein, MD

October 17th 2022

Dr Hetty Carraway reviews the available treatment options for patients with higher-risk MDS, and the biggest challenges of treatment.

Watch

EP. 6: Factors for Consideration when Choosing an Appropriate Treatment for Higher-Risk Myelodysplastic Syndrome

Hetty E. Carraway, MD;Eytan M. Stein, MD

October 17th 2022

Eytan M. Stein, MD, outlines the biggest factors to consider when choosing a treatment for higher-risk MDS, including the differences in quality-of-life for patients.

Watch

EP. 7: The Role of Allogeneic Stem Cell Transplant in Myelodysplastic Syndrome

Hetty E. Carraway, MD;Eytan M. Stein, MD

October 20th 2022

Hetty Carraway, MD, illustrates the role of allogenic stem cell transplant in MDS and the criteria used to determine a patient’s eligibility.

Watch

EP. 8: The Role of Hypomethylating Agents (HMAs) in Higher-Risk Myelodysplastic Syndrome Treatment

Hetty E. Carraway, MD;Eytan M. Stein, MD

October 20th 2022

Key opinion leaders describe the role of hypomethylating agents in treating higher-risk MDS and the treatment options after HMA failure.

Watch

EP. 9: Magrolimab plus Azacitidine for Myelodysplastic Syndrome

Hetty E. Carraway, MD;Eytan M. Stein, MD

October 27th 2022

Drs Stein and Carraway explain the rationale for a magrolimab and azacitidine combination treatment for patients with higher-risk MDS with supporting data from 2 clinical trials.

Watch

EP. 10: Potential Shift in the Treatment Paradigm of Higher-Risk MDS with Magrolimab

Hetty E. Carraway, MD;Eytan M. Stein, MD

October 27th 2022

Dr Hetty Carraway muses on whether magrolimab plus azacitadine will be used as a standard treatment for higher-risk MDS in the future.

Watch

EP. 11: Treating Patients with Myelodysplastic Syndrome and IDH or TP53 Mutations

Hetty E. Carraway, MD;Eytan M. Stein, MD

November 4th 2022

Eytan M. Stein, MD, discusses how to treat patients with MDS who have IDH or TP53 mutations, and whether there is a role for targeted therapy in this patient population.

Watch

EP. 12: Unmet Needs for Patients with Higher-Risk Myelodysplastic Syndrome

Hetty E. Carraway, MD;Eytan M. Stein, MD

November 4th 2022

Dr Carraway highlights some of the most urgent unmet needs for patients with higher-risk MDS.

Watch

EP. 13: ENHANCE-2 Trial of Magrolimab plus Azacitidine in AML

Hetty E. Carraway, MD;Eytan M. Stein, MD

November 10th 2022

Dr Stein explains clinical trial data on the use of magrolimab plus azacitidine for patients with TP53-mutated AML.

Watch

EP. 14: ENHANCE-3 Trial of Magrolimab in Combination with Venetoclax and Azacitidine in AML